AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25027335 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐CPA in early cervical cancer group
Number of subjects: 90
Study 25027335 — intervention group
Group type: COMPARATOR
Intervention: MVD in high-grade CIN group
Number of subjects: 90
Study 25027335 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of MVD with ultrasound parameters
Number of subjects: 90
Study 25027335 — intervention group
Group type: COMPARATOR
Intervention: Postoperative CIN group
Number of subjects: 90
Study 22166903 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (15 μg/kg ideal bodyweight per h) for up to 7 days
Number of subjects: 326
Study 22166903 — intervention group
Group type: COMPARATOR
Intervention: Placebo for up to 7 days
Number of subjects: 326
Study 20702657 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant EBA‐175 vaccine with aluminum phosphate adjuvant (5, 20, 80, or 160 μg) administered at 0, 1, and 6 months
Number of subjects: 26
Study 20702657 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant EBA‐175 vaccine with aluminum phosphate adjuvant (3 doses at any concentration)
Number of subjects: 26
Study 20702657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 17717960 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0, 1, or 10 mmol/L)
Number of subjects: 47
Study 17717960 — intervention group
Group type: COMPARATOR
Intervention: Glutamate (0.2 mL, 1 mol/L)
Number of subjects: 47
Study 15834239 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer Group (interactive computer program before counseling)
Number of subjects: 211
Study 15834239 — intervention group
Group type: COMPARATOR
Intervention: Counselor Group (standard genetic counseling)
Number of subjects: 211
Study 15834239 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer Group
Number of subjects: 211
Study 15834239 — intervention group
Group type: COMPARATOR
Intervention: Counselor Group
Number of subjects: 211
Study 11934776 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire with multiple choice questions about terms of test accuracy and a clinical vignette with the results of a diagnostic test described in three different ways.
Number of subjects: 263
Study 11934776 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing the scan's sensitivity and specificity
Number of subjects: 263
Study 11934776 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple wording of the likelihood ratio
Number of subjects: 263
Study 10778622 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg per day)
Number of subjects: 32
Study 10778622 — intervention group
Group type: COMPARATOR
Intervention: Control (no selegiline)
Number of subjects: 32
Study 8580384 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐1 alpha (0.03 g/kg as a 30 minute infusion daily for 5 days)
Number of subjects: 14
Study 8580384 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐2 (6 x 10(5) IU/kg every 8 hours for 5 days)
Number of subjects: 14
Study 8580384 — intervention group
Group type: COMPARATOR
Intervention: IL‐6 (5-day continuous infusion)
Number of subjects: 14
Study 31904708 — intervention group
Group type: EXPERIMENTAL
Intervention: Partners with a maximum age difference of 0 years (same-age partner)
Number of subjects: 5351
Study 31904708 — intervention group
Group type: EXPERIMENTAL
Intervention: Partners with a maximum age difference of 10 years older
Number of subjects: 5351
Study 31904708 — intervention group
Group type: EXPERIMENTAL
Intervention: Partners with a maximum age difference of 15 years older
Number of subjects: 5351
Study 31904708 — intervention group
Group type: EXPERIMENTAL
Intervention: Partners with a maximum age difference of 15 years older for AGYW ages 15-16 years
Number of subjects: 5351
Study 31904708 — intervention group
Group type: EXPERIMENTAL
Intervention: Partners with a maximum age difference of 8-11 years older for AGYW ages 17-18 years
Number of subjects: 5351
Study 31904708 — intervention group
Group type: EXPERIMENTAL
Intervention: Partners for AGYW ages 19-21 years
Number of subjects: 5351
Study 31567579 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac with opioid medication
Number of subjects: 128
Study 31567579 — intervention group
Group type: COMPARATOR
Intervention: Opioids alone (Control)
Number of subjects: 128
Study 28513346 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation and Problem Solving (PEPS) therapy
Number of subjects: 444
Study 28513346 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 444
Study 25677244 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional dentifrice (1000 ppm F)
Number of subjects: 0
Study 25677244 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fluoride dentifrice (5000 ppm F)
Number of subjects: 0
Study 25677244 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice (fluoride free)
Number of subjects: 0
Study 23778325 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 117
Study 23778325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 21262886 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental protocol (automated ABR testing first, followed by OAE testing if ABR not passed)
Number of subjects: 2167
Study 21262886 — intervention group
Group type: COMPARATOR
Intervention: Standard WIN protocol (OAE testing first, followed by automated ABR testing if OAE not passed)
Number of subjects: 2167
Study 21262886 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental protocol
Number of subjects: 2167
Study 19731968 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 20-30 mg/day
Number of subjects: 1294
Study 19731968 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 7-10 mg/day
Number of subjects: 1294
Study 17324745 — intervention group
Group type: EXPERIMENTAL
Intervention: bisoprolol (5 mg)
Number of subjects: 208
Study 17324745 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan (50 mg)
Number of subjects: 208
Study 17324745 — intervention group
Group type: EXPERIMENTAL
Intervention: amlodipine (5 mg)
Number of subjects: 208
Study 17324745 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide (25 mg)
Number of subjects: 208
Study 17324745 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 208
Study 15054155 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular triamcinolone hexacetonide with methotrexate
Number of subjects: 38
Study 15054155 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular triamcinolone hexacetonide without methotrexate (control)
Number of subjects: 38
Study 11319656 — intervention group
Group type: EXPERIMENTAL
Intervention: Six meals (6vs2)
Number of subjects: 26
Study 11319656 — intervention group
Group type: COMPARATOR
Intervention: Two meals (6vs2)
Number of subjects: 26
Study 11319656 — intervention group
Group type: EXPERIMENTAL
Intervention: Six meals (6+vs2+)
Number of subjects: 26
Study 11319656 — intervention group
Group type: COMPARATOR
Intervention: Two meals (6+vs2+)
Number of subjects: 26
Study 11319656 — intervention group
Group type: EXPERIMENTAL
Intervention: Six meals (6+vsAMFAST)
Number of subjects: 26
Study 11319656 — intervention group
Group type: COMPARATOR
Intervention: Morning fast (6+vsAMFAST)
Number of subjects: 26
Study 11319656 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal frequency (6vs2, 6+vs2+, 6+vsAMFAST)
Number of subjects: 26
Study 9713916 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 10(6) U IFN alpha (Group A)
Number of subjects: 0
Study 9713916 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 10(6) U IFN gamma (Group B)
Number of subjects: 0
Study 9713916 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 x 10(6) U IFN alpha plus 1.5 x 10(6) U IFN gamma (Group C)
Number of subjects: 0
Study 9713916 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 10(6) U IFN alpha plus 1.5 x 10(6) U IFN gamma (Group D)
Number of subjects: 0
Study 7979935 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% benzocaine spray
Number of subjects: 16
Study 7979935 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 16
Study 7979935 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (benzocaine and placebo)
Number of subjects: 16
Study 7979935 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthetic (benzocaine)
Number of subjects: 16
Study 2658886 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated control of sodium nitroprusside administration
Number of subjects: 180
Study 2658886 — intervention group
Group type: COMPARATOR
Intervention: Manual control of sodium nitroprusside administration
Number of subjects: 180
Study 952694 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoperidine
Number of subjects: 50
Study 952694 — intervention group
Group type: COMPARATOR
Intervention: Halothane 0.5%
Number of subjects: 50
Study 31819387 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol + Curcumin (500 mg each daily)
Number of subjects: 40
Study 31819387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29088038 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous posterior lumbar plexus block (PNB)
Number of subjects: 159
Study 29088038 — intervention group
Group type: COMPARATOR
Intervention: PAI with ropivacaine, ketorolac, and epinephrine (PAI-R)
Number of subjects: 159
Study 29088038 — intervention group
Group type: EXPERIMENTAL
Intervention: PAI with liposomal bupivacaine, ketorolac, and epinephrine (PAI-L)
Number of subjects: 159
Study 26698120 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (12.9 mmoles nitrate)
Number of subjects: 21
Study 26698120 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nitrate-depleted beetroot juice)
Number of subjects: 21
Study 24026599 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual financial incentives
Number of subjects: 125
Study 24026599 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice-level financial incentives
Number of subjects: 125
Study 24026599 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined financial incentives
Number of subjects: 125
Study 24026599 — intervention group
Group type: COMPARATOR
Intervention: Control group (no incentives)
Number of subjects: 125
Study 21460146 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (detailed instruction)
Number of subjects: 10
Study 21460146 — intervention group
Group type: COMPARATOR
Intervention: Group A (basic instruction)
Number of subjects: 10
Study 21460146 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 10
Study 21460146 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of abnormal profiles
Number of subjects: 10
Study 18095965 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-ketamine (1 mg.kg(‐1) ketamine + 1.2 mg.kg(‐1) propofol)
Number of subjects: 32
Study 18095965 — intervention group
Group type: COMPARATOR
Intervention: Propofol-fentanyl (1 microg.kg(‐1) fentanyl + 1.2 mg.kg(‐1) propofol)
Number of subjects: 32
Study 17153882 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy formulas and rice formula
Number of subjects: 50
Study 17153882 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey hydrolysates
Number of subjects: 50
Study 17153882 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed hydrolysates and casein hydrolysates
Number of subjects: 50
Study 17153882 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed hydrolysate 1
Number of subjects: 50
Study 17153882 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide weight of each formula
Number of subjects: 50
Study 12698670 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma endothelin-1 levels
Number of subjects: 83
Study 10740940 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine deprivation (6 hr)
Number of subjects: 56
Study 10740940 — intervention group
Group type: COMPARATOR
Intervention: No nicotine deprivation
Number of subjects: 56
Study 8616947 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (30 g, intravenous infusion, 60 minutes)
Number of subjects: 0
Study 8616947 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 (40 microgram, intravenous infusion, 60 minutes)
Number of subjects: 0
Study 8616947 — intervention group
Group type: COMPARATOR
Intervention: Placebo (150 mL 0.9% saline, intravenous infusion, 60 minutes)
Number of subjects: 0
Study 1412677 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 24
Study 3907738 — intervention group
Group type: EXPERIMENTAL
Intervention: sobrerol 400 mg day-1 for 14 days
Number of subjects: 23
Study 3907738 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 23
Study 28248838 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-Based Crisis Intervention (FBCI)
Number of subjects: 142
Study 28248838 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 142
Study 29703266 — intervention group
Group type: EXPERIMENTAL
Intervention: Early and sustained prophylactic hypothermia to 33 °C for 72 hours
Number of subjects: 511
Study 29703266 — intervention group
Group type: COMPARATOR
Intervention: Standard normothermia maintained at a core temperature of 37 °C
Number of subjects: 511
Study 27217308 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening Families Program:10-14
Number of subjects: 14
Study 25310007 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based intervention
Number of subjects: 2099
Study 25310007 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-based intervention
Number of subjects: 2099
Study 25310007 — intervention group
Group type: COMPARATOR
Intervention: Control condition (general text-based advice)
Number of subjects: 2099
Study 20673250 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 30
Study 20673250 — intervention group
Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 30
Study 20673250 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 30
Study 19184428 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide (group A)
Number of subjects: 95
Study 19184428 — intervention group
Group type: COMPARATOR
Intervention: No metoclopramide (group B)
Number of subjects: 95
Study 18076258 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine squat-jump at 21.6% of 1RM for peak power output
Number of subjects: 18
Study 18076258 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine squat-jump at 39.0% of 1RM for mean power output
Number of subjects: 18
Study 18076258 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in load around Pmax
Number of subjects: 18
Study 18076258 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard deviations about means for peak and mean power
Number of subjects: 18
Study 15367045 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg/day)
Number of subjects: 195
Study 15367045 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine XR (225 mg/day)
Number of subjects: 195
Study 11246060 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive trial (ICARUS Israel carvedilol study, exercise study of candesartan cilexetil)
Number of subjects: 70
Study 11246060 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative or neutral trial (MACH‐1 trial of mibefradil, REACH trial of bosentan, CASCO trial of calcium sensitizer, ecadotril trial of neutral endopeptidase inhibitor)
Number of subjects: 70
Study 11246060 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive trial
Number of subjects: 70
Study 11246060 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative or neutral trial
Number of subjects: 70
Study 9768823 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Number of subjects: 0
Study 9768823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7978587 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal midazolam (0.45 mg/kg)
Number of subjects: 34
Study 7978587 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 34
Study 2637586 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth Weight (BW) formula: 3 * BW (Kg) + 9 (cm)
Number of subjects: 120
Study 2637586 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Body Length (TBL) formula: 1/3 TBL (cm)
Number of subjects: 120
Study 2637586 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprasternal Notch to Pubic Symphysis Length (SSL) formula: SSL (cm)
Number of subjects: 120
Study 2637586 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder to Umbilicus Length (SUL) formula: SUL (cm) + 2 (cm)
Number of subjects: 120
Study 2637586 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation coefficients (rs) between inserted length of UAC and each of the four parameters (BW, TBL, SSL, SUL)
Number of subjects: 120
Study 4156290 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium clorazepate (15 mg. at night)
Number of subjects: 50
Study 4156290 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam (1 mg. t.d.s.)
Number of subjects: 50
Study 4156290 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium clorazepate
Number of subjects: 50
Study 4156290 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 50
Study 31725441 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour simulation-based leadership training
Number of subjects: 79
Study 31725441 — intervention group
Group type: COMPARATOR
Intervention: Standard orientation (control)
Number of subjects: 79
Study 31725441 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadership behaviors (mediated effect)
Number of subjects: 79
Study 30785198 — intervention group
Group type: COMPARATOR
Intervention: GEMOX (gemcitabine 1000 mg/m2 on days 1 and 8, and oxaliplatin 100 mg/m2 on day 1)
Number of subjects: 222
Study 30785198 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX (capecitabine 1000 mg/m2, twice daily, on days 1‐14 and oxaliplatin 130 mg/m2 on day 1)
Number of subjects: 222
Study 30785198 — intervention group
Group type: COMPARATOR
Intervention: GEMOX
Number of subjects: 222
Study 30785198 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX
Number of subjects: 222
Study 29768118 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib 250 mg twice daily
Number of subjects: 343
Study 29768118 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (pemetrexed 500 mg/m2 plus cisplatin 75 mg/m2 or carboplatin)
Number of subjects: 343
Study 27306520 — intervention group
Group type: COMPARATOR
Intervention: BBP (blackberry puree without ethanol)
Number of subjects: 18
Study 27306520 — intervention group
Group type: EXPERIMENTAL
Intervention: BBP 12% (blackberry puree with 12% ethanol)
Number of subjects: 18
Study 25236611 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Traffic Light label
Number of subjects: 1500
Study 25236611 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Star Rating label
Number of subjects: 1500
Study 25236611 — intervention group
Group type: COMPARATOR
Intervention: Nutrition Information Panel (Control)
Number of subjects: 1500
Study 21778912 — intervention group
Group type: COMPARATOR
Intervention: Walking (W)
Number of subjects: 44
Study 21778912 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking plus Resistance Training (WRT)
Number of subjects: 44
Study 20356944 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual invitation to mammography from age 40 or 41
Number of subjects: 53884
Study 16938161 — intervention group
Group type: COMPARATOR
Intervention: Group G (General anaesthesia with propofol 2 mg kg‐1 and fentanyl 100 microg)
Number of subjects: 33
Study 16938161 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S (Spinal anaesthesia with propofol infusion at 2 mg kg‐1 h‐1 after a 0.2 mg kg‐1 bolus dose and fentanyl 100 microg)
Number of subjects: 33
Study 16938161 — intervention group
Group type: EXPERIMENTAL
Intervention: Group T (TIVA with propofol 2 mg kg‐1 and fentanyl 100 microg)
Number of subjects: 33
Study 16938161 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S (Spinal anaesthesia)
Number of subjects: 33
Study 16938161 — intervention group
Group type: EXPERIMENTAL
Intervention: Group T (TIVA)
Number of subjects: 33
Study 16938161 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 33
Study 16249704 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported adherence
Number of subjects: 258
Study 16249704 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir AUC
Number of subjects: 258
Study 11888453 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted surgery (VAS)
Number of subjects: 62
Study 11888453 — intervention group
Group type: COMPARATOR
Intervention: Conventional thyroid lobectomy (COS)
Number of subjects: 62
Study 10761402 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine before and after ALT (B/B)
Number of subjects: 80
Study 10761402 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine before and placebo after ALT (B/P)
Number of subjects: 80
Study 10761402 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo before and brimonidine after ALT (P/B)
Number of subjects: 80
Study 10761402 — intervention group
Group type: COMPARATOR
Intervention: Placebo before and after ALT (P/P)
Number of subjects: 80
Study 7723446 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail-out/mail-back method
Number of subjects: 697
Study 7723446 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-out/assisted method
Number of subjects: 697
Study 7723446 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home interview method
Number of subjects: 697
Study 7723446 — intervention group
Group type: COMPARATOR
Intervention: Mail-out/mail-back or hand-out/assisted method (nonresponders reassigned)
Number of subjects: 697
Study 2035380 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 240 mg/day
Number of subjects: 31
Study 2035380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 2035380 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 31
Study 6271002 — intervention group
Group type: EXPERIMENTAL
Intervention: High cellulose diet
Number of subjects: 13
Study 6271002 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cellulose diet
Number of subjects: 13
Study 30997542 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine sponge dressings
Number of subjects: 18286
Study 30997542 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel dressings
Number of subjects: 18286